Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia  

作　　者：Xiangyu Zhao Haotian Wu Yifei Cheng Zhengli Xu Yuhong Chen Yingjun Chang Yu Wang Xiaohui Zhang Lanping Xu Xiaojun Huang 

机构地区：[1]Peking University People’s Hospital,Peking University Institute of Hematology,Department of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,National Clinical Research Center for Hematologic Disease,Xicheng District,Beijing 100044,China [2]Peking University Health Science Center,Beijing 100191,China [3]Peking-Tsinghua Center for Life Sciences,Beijing 100871,China

出　　处：《Chinese Medical Journal》2023年第16期2011-2013,共3页中华医学杂志（英文版）

基　　金：supported by grants from the National Natural Science Foundation of China(Nos.82070184 and 82270228);sponsored by Beijing Nova Program(No.20220484235);Peking University People’s Hospital Research and Development Funds(No.RDL2021-01)

摘　　要：To the Editor:For recipients with relapsed/refractory(R/R)B-cell acute lymphoblastic leukemia(B-ALL),allogeneic hematopoietic stem cell transplantation(allo-HSCT)often fails to provide them with a satisfactory prognosis.The chimeric antigen receptor T(CAR-T)cells are proven to be safe and effective for these patients.[1]But there are few published studies assessing the advantages of CAR-T compared to traditional chemotherapy as a bridging treatment followed by HSCT.Consequently,we conducted this study to confirm whether children and young adult R/R B-ALL patients with CAR-T therapy could expect a better post-HSCT prognosis,compared to R/R patients only receiving traditional chemotherapy before transplantation.

关 键 词：chemotherapy LYMPHOBLASTIC PROGNOSIS 

分 类 号：R733.71[医药卫生—肿瘤]